Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
暂无分享,去创建一个
M. Keating | S. O'brien | J. Burger | W. Wierda | S. Wen | S. Faderl | A. Ferrajoli | X. Badoux | R. Sargent
[1] G. Morgan,et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. , 2012, Blood.
[2] T. Kipps,et al. Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study) , 2011 .
[3] J. Reuben,et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. , 2011, Blood.
[4] H. Döhner,et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Z. Estrov,et al. Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia , 2011, Cancer.
[6] E. Iannitto,et al. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study , 2011, British journal of haematology.
[7] P. L. Bergsagel,et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] H. Kantarjian,et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. , 2011, Blood.
[9] M. Tucker,et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Kimby,et al. Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study) , 2010 .
[11] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[12] A. Chanan-Khan,et al. Management of patients with chronic lymphocytic leukemia treated with lenalidomide. , 2010, Clinical journal of oncology nursing.
[13] A. Tsimberidou,et al. Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options , 2010, Leukemia & lymphoma.
[14] Lisa L. Smith,et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. , 2010, Blood.
[15] P. Ganly,et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Dyer,et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Czuczman,et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics , 2010, Leukemia & lymphoma.
[18] H. Kantarjian,et al. Long Term Outcome Following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia. , 2009 .
[19] J. Gribben,et al. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug , 2009, Haematologica.
[20] Thomas E. Hughes,et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia , 2009, Haematologica.
[21] R. Schlenk,et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] L. Rassenti,et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia , 2008, Leukemia.
[23] K. Do,et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. , 2008, Blood.
[24] George Muller,et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.
[25] J. Byrd,et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.
[26] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[27] Z. Estrov,et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. , 2008, Blood.
[28] C. Pui,et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Lisa L. Smith,et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] B. Cheson,et al. Lenalidomide for the treatment of B-cell malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Czuczman,et al. Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo , 2007, British journal of haematology.
[32] J. Zeldis,et al. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Deborah A. Bowen,et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features , 2007, Leukemia & lymphoma.
[34] M. Czuczman,et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] H. Kantarjian,et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Thomas J. Smith,et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Arthur Weiss,et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.
[38] J. Byrd,et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. , 2004, Clinical lymphoma.
[39] E. Thiel,et al. Remission Induction Using Alemtuzumab can Permit Chemotherapy-refractory Chronic Lymphocytic Leukemia (CLL) Patients to Undergo Allogeneic Stem Cell Transplantation , 2004, Leukemia & lymphoma.
[40] J. Byrd,et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.
[41] H. Kantarjian,et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] M. Grever,et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[44] M. Hallek,et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. , 2005, Haematologica.